glp 1 incretin Biology of Incretins: GLP-1 and GIP Multifunctional incretin peptides in therapies

Currently, there are ten classes of orally available pharmacological agents to treat T2DM: 1) sulfonylureas, 2) meglitinides, 3) metformin (a biguanide), 4) thiazolidinediones (TZDs), 5) alpha glucosidase inhibitors, 6) dipeptidyl peptidase IV (DPP-4) inhibitors, 7) bile acid sequestrants, 8) dopamine agonists, 9) sodium-glucose transport protein 2 (SGLT2) inhibitors and 10) oral glucagon like peptide 1 (GLP-1) receptor agonists

Among the individual GLP-1RAs assessed, the largest reductions in CV risk, HbA1c, and weight outcomes were observed with combination therapy with SGLT2i and once weekly semaglutide for T2D

Simply apply to clean, dry skin

Ready to lose weight and improve your quality of life

Studies are demonstrating a plethora of positive effects on cardiovascular health, renal disease and liver disease, which may be directly related to the mitigation of the diabetes or obesity-associated risks of these complications or possibly direct protective effects